YD Bio Limited Ordinary Shares (YDES) Financial Ratios
5 years of historical data (2020–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
3.33
—
5yr avg: N/A
ROE
↓
-42.7%
↑-603% vs avg
5yr avg: -6.1%
30Y Low-43%·High8%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
YDES Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
YD Bio Limited Ordinary Shares currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Market Cap | $22M | — | — | — | — | — |
| Enterprise Value | $19M | — | — | — | — | — |
| P/E Ratio → | -9.45 | — | — | — | — | — |
| P/S Ratio | 42.99 | — | — | — | — | — |
| P/B Ratio | 3.33 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
YDES EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
YDES Profitability
Margins and return-on-capital ratios measuring operating efficiency
YD Bio Limited Ordinary Shares earns an operating margin of -286.5%. Operating margins have compressed from -2.8% to -286.5% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -42.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | 30.4% | 30.4% | 43.8% | — | — | — |
| Operating Margin | -286.5% | -286.5% | -2.8% | — | — | — |
| Net Profit Margin | -276.6% | -276.6% | 3.9% | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| ROE | -42.7% | -42.7% | 0.2% | 6.3% | 8.3% | -2.5% |
| ROA | -39.3% | -39.3% | 0.1% | 5.6% | 7.4% | -2.2% |
| ROIC | -63.3% | -63.3% | -0.1% | -2.9% | -1.2% | — |
| ROCE | -44.1% | -44.1% | -0.2% | -3.6% | -1.5% | -0.3% |
YDES Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $3M exceeds total debt of $22555, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 2.07 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.47 | -1.72 | -0.00 | -0.00 | -0.01 |
| Net Debt / EBITDA | — | — | — | -0.00 | -0.00 | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -1893.69 | -1893.69 | -4.59 | — | — | — |
Net cash position: cash ($3M) exceeds total debt ($22555)
YDES Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
YD Bio Limited Ordinary Shares's current ratio of 13.18x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 0.04x to 13.18x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Current Ratio | 13.18 | 13.18 | 0.91 | 0.04 | 0.06 | 2.75 |
| Quick Ratio | 13.04 | 13.04 | 0.68 | 0.04 | 0.06 | 2.75 |
| Cash Ratio | 11.91 | 11.91 | 0.29 | 0.00 | 0.00 | 2.30 |
| Asset Turnover | — | 0.07 | 1.09 | — | — | — |
| Inventory Turnover | 9.51 | 9.51 | 2.83 | — | — | — |
| Days Sales Outstanding | — | 187.95 | 102.61 | — | — | — |
YDES Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
YD Bio Limited Ordinary Shares does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $4M | $70M | $9M | $15M | $15M |
Peer Comparison
Compare YDES with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 YDESYou | $22M | -9.4 | — | — | 30.4% | -286.5% | -42.7% | -63.3% | — |
 BTBT | $589M | 9.2 | 8.5 | — | 61.9% | 16.8% | 9.2% | 6.5% | 0.2 |
 NUVB | $2B | -8.0 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 ZLAB | $2B | -12.4 | — | — | 58.6% | -49.9% | -22.6% | -42.8% | — |
 ZYME | $2B | -24.6 | 0.3 | — | 89.8% | -87.3% | -26.7% | -25.9% | 0.0 |
 IQ | $1B | 10.7 | 10.3 | 4.1 | 24.9% | 6.2% | 6.0% | 5.8% | 7.8 |
 TIGR | $628M | 17.9 | 2.8 | 0.8 | 65.0% | 35.6% | 10.5% | 13.8% | 1.2 |
 LEGN | $5B | -8.9 | — | — | 60.3% | -13.3% | -29.1% | -12.7% | — |
 CGEN | $256M | -17.9 | — | 5.2 | 71.5% | -53.4% | -23.6% | -24.1% | — |
 NVAX | $2B | 3.6 | 2.6 | — | 93.7% | 50.1% | — | — | 0.4 |
 OCGN | $487M | -6.3 | — | — | 45.9% | -1425.7% | -776.9% | -1565.6% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
See YDES's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs YDES Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare YDES vs BTBT
Side-by-side business, growth, and profitability comparison vs Bit Digital, Inc..
Start ComparisonYDES — Frequently Asked Questions
Quick answers to the most common questions about buying YDES stock.
What is YD Bio Limited Ordinary Shares's P/E ratio?
YD Bio Limited Ordinary Shares's current P/E ratio is -9.4x. This places it at the 50th percentile of its historical range.
What is YD Bio Limited Ordinary Shares's ROE?
YD Bio Limited Ordinary Shares's return on equity (ROE) is -42.7%. The historical average is -6.1%.
Is YDES stock overvalued?
Based on historical data, YD Bio Limited Ordinary Shares is trading at a P/E of -9.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are YD Bio Limited Ordinary Shares's profit margins?
YD Bio Limited Ordinary Shares has 30.4% gross margin and -286.5% operating margin.